Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome

Marc Tischkowitz, Chrystelle Colas, Sjaak Pouwels, Tanya M. Bisseling, Virginie Bubien, F. Caux, Nathalie Chabbert‐Buffet, Chrystelle Colas, Sophie Da Mota Gomes, Martin Gotthardt,

European Journal of Human Genetics · 2020 · 135 citations · 12 references

DOIFull text

Open access

Concepts

TL;DR

PTEN hamartoma tumour syndrome predisposes to breast, thyroid, renal, endometrial, colorectal cancers and melanoma, yet no international consensus on surveillance exists and current guidelines rely on expert opinion. This guideline seeks to evaluate the effectiveness of surveillance in PHTS by highlighting the limited evidence base and the need for prospective studies. The authors performed a comprehensive literature review and assembled multidisciplinary clinicians and patient representatives to develop the surveillance recommendations. The guideline recommends surveillance for breast, thyroid, and renal cancers, offers limited guidance for endometrial, colon, and skin sites, and stresses a coordinated multidisciplinary approach with significant patient commitment.

Abstract

PTEN hamartoma tumour syndrome is a diverse multi-system disorder predisposing to the development of hamartomatous growths, increasing risk of breast, thyroid, renal cancer, and possibly increasing risk of endometrial cancer, colorectal cancer and melanoma. There is no international consensus on cancer surveillance in PHTS and all current guidelines are based on expert opinion. A comprehensive literature review was undertaken and guidelines were developed by clinicians with expertise from clinical genetics, gynaecology, endocrinology, dermatology, radiology, gastroenterology and general surgery, together with affected individuals and their representatives. Recommendations were put forward for surveillance for breast, thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin. The proposed cancer surveillance recommendations for PHTS require a coordinated multidisciplinary approach and significant patient commitment. The evidence base for cancer surveillance in this guideline are limited, emphasising the need for prospective evaluation of the effectiveness of surveillance in the PHTS population.

References

12